Middle East In-Vitro Diagnostics Market

Plastic Optic Fiber Market Report Thumbnail

Middle East In-Vitro Diagnostics Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and by End User (Stand Alone, Laboratory, Hospitals, Academics and Medical Schools, Point of Care Testing, and Other End Users) – Opportunity Analysis and Industry Forecast, 2024–2030

Industry: Healthcare | Publish Date: 20-Dec-2024 | No of Pages: 139 | No. of Tables: 104 | No. of Figures: 69 | Format: PDF | Report Code : HC2367

  • Facebook
  • Linkedin
  • Whatsapp

Market Overview

The Middle East In-Vitro Diagnostics Market size was valued at USD 2.41 billion in 2023, and is predicted to reach USD 3.48 billion by 2030, at a CAGR of 4.9% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.

IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology. These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, immunodiagnostic experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges. 

Increased Investment in Advancing Healthcare Sector Drives the Market Growth

The increased investment in advancing Saudi Arabia's healthcare sector serves as a significant driver for the growth of the in-vitro diagnostics market in the country. According to World Trade Organization, as part of Vision 2030, the Saudi Arabian Government aims to allocate more than USD 65 billion for the enhancement of the country's healthcare infrastructure. This initiative involves restructuring and privatizing healthcare services, establishing 21 health clusters nationwide, and expanding e-health services.

With such increase in healthcare investment there is a growing need for accurate and efficient diagnostic tools. This surge in demand for immunodiagnostics technologies is not only propelling growth in Saudi Arabia's diagnostics market but also influencing trends across the broader Middle East region. 

 

Rising Prevalence of Various Non-Communicable Diseases Boosts the Market Growth

In Qatar, the in-vitro diagnostics industry is showing a significant growth due to the prevalence of various non-communicable diseases. Noncommunicable diseases and their associated risk factors currently stand as the primary contributors to morbidity, mortality, and disability in Qatar.

As outlined in the Qatar National Health Strategy 2018-2022, more than two-thirds of all deaths in the country are linked to chronic conditions, with cardiovascular disease accounting for 24 percent, cancer for 18 percent, and diabetes for 7 percent of these fatalities.

With non-communicable diseases being the leading cause of morbidity, mortality, and disability, there is a growing demand for advanced diagnostic solutions to accurately diagnose, monitor, and manage these chronic conditions.

 

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the Middle East in-vitro diagnostics market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.

Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing (POCT) Solutions in IVD Creates Market Opportunity

Point-of-care testing (POCT) is poised to significantly drive the Middle East in-vitro diagnostics market demand in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac biomarkers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

 

Competitive Landscape

The promising players operating in the Middle East in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Middle East In-Vitro Diagnostics Market Key Segments

By Type

  • Reagents

  • Instruments

  • Software & Services

By Technique

  • Immunodiagnostics

    • Enzyme-Linked Immunosorbent Assay (ELISA)

    • Rapid Tests

    • Chemiluminescence Immunoassay (CLIA)

    • Enzyme-linked Immunosorbent spot (ELISpot)

    • Radioimmunoassay (RIA)

    • Western Blot

  • Hematology

  • Molecular Diagnostics

    • PCR

    • INAAT 

    • Hybridization 

    • DNA diagnostics 

    • Microarray 

    • Other Molecular Diagnostics

  • Tissue Diagnostics

  • Clinical Chemistry

    • Basic Metabolic Panel 

    • Liver Panel

    • Renal Profile

    • Lipid Profile

    • Thyroid Function Panel 

    • Electrolyte Panel 

    • Speciality Chemicals

  • Other IVD Techniques

By Application

  • Infectious Diseases

  • Cancer

  • Cardiac Diseases

  • Immune System Disorders

  • Nephrological Diseases

  • Gastrointestinal Diseases

  • Others

By End User

  • Stand Alone Laboratory

  • Hospitals

  • Academics and Medical Schools

  • Point of Care Testing

  • Other End Users

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size Value in 2023

USD 2.41 billion

Revenue Forecast in 2030

USD 3.48 billion

Value Growth Rate

CAGR of 4.9% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Billion (USD)

Growth Factors

  • Increased Investment in Advancing Healthcare Sector Drives the Market Growth.
  • Rising Prevalence of Various Non-Communicable Diseases Boosts the Market Growth.

Companies Profiled

10

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

  • Roche Holding AG

  • Abbott Laboratories

  • Thermo Fisher Scientific Inc.

  • Danaher Corporation

  • Becton, Dickinson and Company

  • Siemens Healthineers AG

  • bioMérieux SA

  • Sysmex Corporation

  • QIAGEN N.V.

  • Bio-Rad Laboratories, Inc.

Bar chart Pie chart Pie chart

Frequently Asked Questions

The Middle East in-vitro diagnostics market revenue is estimated to reach USD 3.48 billion by 2030.

The key players operating in the Middle East in-vitro diagnostics market include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

The Middle East in-vitro diagnostics market size was estimated at USD 2.41 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the Middle East IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the Middle East in-vitro diagnostics market, in the coming future.

Download Free Sample

Please Enter Full Name

Please Enter Valid Email ID

Please enter Country Code and Phone No

Please enter message

popular
$3,975
$2,975
$5,275
$2,975

This website uses cookies to ensure you get the best experience on our website. Learn more